Treating lymphoma is now a bit EZ-er.

Area of Science:

• Oncology
• Epigenetics
• Hematology

Background:

• Follicular lymphoma (FL) and germinal center diffuse large B-cell lymphoma (GC-DLBCL) often feature mutations in epigenetic regulators.
• Enhancer of zeste homolog 2 (EZH2) is a key epigenetic regulator frequently mutated in these lymphomas.

Purpose of the Study:

• To review the discovery and functional role of EZH2 mutations in lymphomagenesis.
• To discuss the development and approval of tazemetostat for relapsed FL.
• To explore potential future applications of tazemetostat in germinal center-derived lymphomas.

Main Methods:

• Review of preclinical studies on tazemetostat.
• Analysis of clinical trial data supporting tazemetostat's approval.
• Exploration of ongoing research into EZH2 function and tazemetostat's efficacy.

Main Results:

• Tazemetostat is the first approved epigenetic therapy targeting EZH2 for FL treatment.
• Clinical data demonstrated efficacy in relapsed FL, leading to regulatory approval.
• Ongoing research investigates EZH2's role and tazemetostat's broader applicability.

Conclusions:

• Tazemetostat represents a significant advancement in epigenetic therapy for FL.
• Understanding EZH2 mutations and tazemetostat's mechanisms may expand its therapeutic use.
• Further research is crucial for optimizing tazemetostat's application in lymphomas.